Department of General Surgery, Hospital of Hebei Province Crop of Chinese Armed Police Force, Shijiazhuang, Hebei, China.
Department of Otolaryngology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei, China.
World J Surg Oncol. 2023 Jan 24;21(1):22. doi: 10.1186/s12957-023-02899-w.
BACKGROUND: To investigate the relationship between cyclin D2 (CCND2) and miR-206 expression in fine-needle aspiration cytology of thyroid carcinoma. METHODS: A total of 65 patients with thyroid carcinoma were selected as the subjects and 65 patients with benign thyroid nodules were in control group. The fine-needle aspiration cytology of thyroid nodules was performed. CCND2 and miR-206 levels were detected by PCR. RESULTS: Compared with the patients with benign thyroid nodules, the expression level of miR-206 in fine-needle aspiration cytology of thyroid cancer patients decreased significantly and the expression level of CCND2 increased significantly. CCND2 and miR-206 expression was negatively correlated in thyroid cancer tissues. Area under curve (AUC) of miR-206 level in the diagnosis of thyroid cancer was 0.889, and the sensitivity and specificity were 92.3% and 81.5%, respectively. AUC of CCND2 level in the diagnosis of thyroid cancer was 0.837, and the sensitivity and specificity were 67.7% and 89.2%, respectively. The AUC of combined detection of CCND2 and miR-206 in the diagnosis of thyroid cancer was 0.959, and the sensitivity and specificity were 93.8% and 87.7%, respectively. The levels of miR-206 and CCND2 were significantly correlated with TNM staging and lymph node metastasis. CONCLUSIONS: miR-206 and CCND2 may become new biomarkers for clinical diagnosis of thyroid cancer based on the fine-needle aspiration cytology of thyroid nodules.
背景：研究甲状腺癌细针穿刺细胞学中细胞周期蛋白 D2（CCND2）与 miR-206 表达的关系。
方法：选取 65 例甲状腺癌患者作为观察组，同期选取 65 例甲状腺良性结节患者作为对照组，对甲状腺结节进行细针穿刺细胞学检查，采用 PCR 检测 CCND2 和 miR-206 水平。
结果：与甲状腺良性结节患者相比，甲状腺癌患者细针穿刺细胞学中 miR-206 表达水平明显降低，CCND2 表达水平明显升高。甲状腺癌组织中 CCND2 和 miR-206 表达呈负相关。miR-206 水平诊断甲状腺癌的曲线下面积（AUC）为 0.889，灵敏度和特异度分别为 92.3%和 81.5%。CCND2 水平诊断甲状腺癌的 AUC 为 0.837，灵敏度和特异度分别为 67.7%和 89.2%。CCND2 和 miR-206 联合检测诊断甲状腺癌的 AUC 为 0.959，灵敏度和特异度分别为 93.8%和 87.7%。miR-206 和 CCND2 水平与 TNM 分期和淋巴结转移显著相关。
结论：基于甲状腺结节的细针穿刺细胞学，miR-206 和 CCND2 可能成为甲状腺癌临床诊断的新生物标志物。
Hong Kong Med J. 2007-2
Horm Mol Biol Clin Investig. 2020-3-13
Nan Fang Yi Ke Da Xue Xue Bao. 2024-5-20
J Natl Cancer Cent. 2022-2-27
Adv Skin Wound Care. 2022-8-1
Lymphat Res Biol. 2022-4
Cell Mol Biol Lett. 2020-3-17
Biomed Pharmacother. 2019-3-21
Onco Targets Ther. 2019-1-25
Cancer Epidemiol Biomarkers Prev. 2018-7-26
Int J Surg. 2018-4-28
Zotero 插件